Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | TET3 | O43151 | 1/20 | 0.41 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.41 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128270 | 0.98 | AKR1C1 (0.68) | AKR1C1KMT2AMEN1TSHRESR1 | |
| SCHEMBL350266 | 0.91 | APP (0.58) | AKR1C1KMT2AMEN1TSHRESR1 | |
| SCHEMBL1334283 | 0.85 | ESR1 (0.56) | AKR1C1KMT2AMEN1TSHRESR1 | |
| SCHEMBL27974576 | 0.83 | ESR1 (0.57) | AKR1C1KMT2AMEN1TSHRESR1 | |
| SCHEMBL65167 | 0.83 | AKR1C1 (1.00) | AKR1C1KMT2AMEN1TSHRHDAC4 | |
| SCHEMBL21101816 | 0.82 | APP (0.55) | AKR1C1KMT2AMEN1TSHRESR1 | |
| SCHEMBL23920041 | 0.82 | AKR1C1 (0.68) | AKR1C1KMT2AMEN1TSHRHDAC4 | |
| SCHEMBL2817038 | 0.82 | AKR1C1 (0.68) | AKR1C1KMT2AMEN1TSHRHDAC4 | |
| SCHEMBL9966557 | 0.82 | AKR1C1 (0.68) | AKR1C1KMT2AMEN1TSHRHDAC4 | |
| SCHEMBL21873984 | 0.82 | AKR1C1 (0.68) | AKR1C1KMT2AMEN1TSHRHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-0706508-A1 | ANTI-ATHEROSCLEROTIC DIARYL COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001326-A1 | ANTI-ATHEROSCLEROTIC DIARYL COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | AKR1C1 2816/4885KMT2A 124/4885MEN1 3511/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | AKR1C1 2816/4885KMT2A 124/4885MEN1 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.